All In Biotech

Drug Trial Radar · NCT05175352

A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab

A Phase 1, Open-label, Single-sequence Study to Evaluate Potential Disease-mediated Drug-drug Interaction With Selected Cytochrome P450 Substrates in Adult Subjects With Active Eosinophilic Esophagitis Receiving Cendakimab

Last checked: Nov 19, 2026Latest source record: Dec 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Jun 7, 2022

Primary completion

Oct 11, 2024

Study completion Oct 11, 2024

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jan 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study to evaluate the potential for disease-mediated drug-drug interactions between cendakimab and selected substrates of metabolic enzymes in eosinophilic esophagitis participants.

Conditions

  • Eosinophilic Esophagitis

Interventions

  • CendakimabDrug

    Specified dose on specified days

  • CYP substratesDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics - Area under the concentration-time curve calculated from time zero to infinity (AUC0-∞)Time frame: Up to 18 Weeks
  2. Pharmacokinetics - Area under the concentration-time curve calculated from time zero to 12 hours postdose (AUC0-12h)Time frame: Up to 18 Weeks

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Local Institution - 004

    Tucson, Arizona

  • Local Institution - 001

    Los Angeles, California

  • Local Institution - 022

    San Diego, California

  • Local Institution - 016

    Bristol, Connecticut

  • Local Institution - 002

    Inverness, Florida

  • Local Institution - 010

    Miami, Florida

  • Local Institution - 021

    Plantation, Florida

  • Local Institution - 020

    Gurnee, Illinois

  • Local Institution - 008

    Iowa City, Iowa

  • Local Institution - 003

    Albuquerque, New Mexico

  • Local Institution - 018

    Durham, North Carolina

  • Local Institution - 012

    Columbus, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.